Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Novartis

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Novartis' 2013 sales performance.

Novartis

Charting patient pathways with precision for better healthcare

Charting patient pathways with precision for better healthcare Patients and physicians are stronger together and Dunlop, who has more than 20 years’ experience leading patient advocacy programmes and engagement strategies for clients such as AstraZeneca, GSK, Novartis and Pfizer,

Novartis and Voyager Therapeutics agree on gene therapy deal worth 1.7bn

Novartis and Voyager Therapeutics agree on gene therapy deal worth 1.7bn Novartis has announced a licence option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene ... Voyager will receive an initial $54m

Sandoz launches generic oncology treatment in Europe

Sandoz launches generic oncology treatment in Europe Sandoz, a division of Novartis, is a global company working to address unmet medical needs and provide patients with access to generic pharmaceuticals and biosimilars.

Novartis to pay up to $1.5bn for Gyroscope

Novartis to pay up to $1.5bn for Gyroscope There are no approved treatments, making it ‘one of the most significant unmet needs remaining in retinal diseases’, according to Novartis. ... in ocular gene therapies that will position us well to continue developing this promising one-time

Novartis strengthens links with BeiGene in a deal that could be worth up to $1bn

Novartis strengthens links with BeiGene in a deal that could be worth up to $1bn The two companies are already working together after Novartis signed an in-licensing agreement for BeiGene’s anti-PD-1 monoclonal antibody, tislelizumab. ... countries. Basel-based Novartis will also pay a fee of up to $700m if the option is exercised

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Evoke Mind+Matter

We are Evoke Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for...

Latest intelligence

Sustainability
Environment: where does the pharmaceutical industry stand?
...
The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...